1932

Abstract

Over the past decade, considerable advances have been made in the field of allogeneic hematopoietic stem cell transplantation. Recognition that transplanted donor immune cells can cure patients with leukemia has led to the development of nonmyeloablative or “low-intensity” conditioning regimens, which have expanded the application of allogeneic transplantation to a growing number of hematological malignancies. The improved safety and preliminary success of this transplant approach have justified applying allogeneic immunotherapy to patients with treatment-refractory solid tumors.

Loading

Article metrics loading...

/content/journals/10.1146/annurev.med.55.091902.104511
2004-02-18
2024-04-15
Loading full text...

Full text loading...

/content/journals/10.1146/annurev.med.55.091902.104511
Loading
/content/journals/10.1146/annurev.med.55.091902.104511
Loading

Data & Media loading...

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error